Ignite Creation Date:
2024-05-06 @ 12:28 AM
Last Modification Date:
2024-10-26 @ 10:50 AM
Study NCT ID:
NCT01587651
Status:
COMPLETED
Last Update Posted:
2019-01-09
First Post:
2012-04-26
Brief Title:
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
Sponsor:
Daiichi Sankyo
Organization:
Daiichi Sankyo
Study Overview
Official Title:
A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease 2nd Switching Antiplatelet Agents
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SWAP-2
Brief Summary:
This is a Phase 4 multicenter open-label blinded Pharmacodynamic PD results randomized 3-arm parallel-design study of subjects with stable Coronary Artery Disease CAD This study will compare the PD effect of prasugrel 10 mg QD once-daily maintenance dose with ticagrelor 90 mg BID twice daily maintenance dose in subjects with stable CAD who have previously received ticagrelor loading does LD and maintenance dose MD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None